Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
L Degli Esposti, M Andretta, G Di Pasquale, M Gambera, S Saragoni, V Perrone & S Buda. (2019) Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases. Vascular Health and Risk Management 15, pages 429-437.
Read now
Read now
Jeffrey Trocio, Virginia M Rosen, Anu Gupta, Oluwaseyi Dina, Lien Vo, Patrick Hlavacek & Lisa Rosenblatt. (2019) Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings. ClinicoEconomics and Outcomes Research 11, pages 23-49.
Read now
Read now
Jorge Romero, Ricardo Avendano, Juan Carlos Diaz, Jose Taveras, Florentino Lupercio & Luigi Di Biase. (2019) Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?. Expert Review of Cardiovascular Therapy 17:1, pages 31-41.
Read now
Read now
Alpesh Amin, Allison Keshishian, Lien Vo, Qisu Zhang, Oluwaseyi Dina, Chad Patel, Kevin Odell & Jeffrey Trocio. (2018) Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. Journal of Medical Economics 21:3, pages 244-253.
Read now
Read now
Steve Deitelzweig, Amanda Bruno, Jeffrey Trocio, Natalie Tate, Kiran Gupta, Jay Lin & Melissa Lingohr-Smith. (2016) An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Current Medical Research and Opinion 32:3, pages 573-582.
Read now
Read now
Articles from other publishers (14)
Manon Belhassen, Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahé, Mélanie Née, Flore Jacoud, Faustine Dalon, François-Emery Cotté, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse & Nicolas Danchin. (2022) Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. The European Journal of Health Economics 24:6, pages 867-875.
Crossref
Crossref
Sabrina Kepka, Elena-Mihaela Cordeanu, Kevin Zarca, Anne-Sophie Frantz, Patrick Ohlmann, Emmanuel Andres, Pascal Bilbault, Isabelle Durand-Zaleski & Dominique Stephan. (2023) A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. Medicina 59:1, pages 181.
Crossref
Crossref
Daniela Štrosová, Jan Tužil, Barbora Pilnáčková, Lada Lžičařová, Veronika Typovská, Helena Doležalová, Martin Herold & Tomáš Doležal. (2022) Direct costs in patients with nonvalvular atrial fibrillation newly indicated to apixaban: a retrospective‑prospective single‑arm cohort study. Vnitřní lékařství 68:1, pages 26-33.
Crossref
Crossref
Gianluca Grimaldi, Domenica Ancona, Domenico Tricarico, Paolo Stella, Cataldo Procacci, Antonio Germinario, Vito Bavaro, Vito Montanaro & Alessandro Delle Donne. (2021) Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. Pharmaceutics 13:2, pages 252.
Crossref
Crossref
Jonathan C. Hsu & James V. Freeman. (2018) Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology & Therapeutics 104:2, pages 301-310.
Crossref
Crossref
Steve Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Patrick Hlavacek, Melissa Lingohr-Smith, Brandy Menges & Jay Lin. (2018) All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis 24:4, pages 602-611.
Crossref
Crossref
Nai-Fang Chi, Ye Wang, Li-Nien Chien, Shu-Chen Chien & Yu Ko. (2018) Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation. Medical Care 56:5, pages 410-415.
Crossref
Crossref
Steven DeitelzweigXuemei LuoKiran GuptaJeffrey TrocioJack MardekianTammy CurticeMelissa Lingohr-SmithBrandy MengesJay Lin. (2017) Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy 23:11, pages 1191-1201.
Crossref
Crossref
Andreas Zirlik & Christoph Bode. (2016) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 43:3, pages 365-379.
Crossref
Crossref
Anene Ukaigwe, Pragya Shrestha, Paras Karmacharya, Sarah K. Hussain, Soraya Samii, Mario D. Gonzalez, Deborah Wolbrette & Gerald V. Naccarrelli. (2016) Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology 48:2, pages 223-233.
Crossref
Crossref
Hisham Badreldin, Hunter Nichols, Jessica Rimsans & Danielle Carter. (2016) Evaluation of anticoagulation selection for acute venous thromboembolism. Journal of Thrombosis and Thrombolysis 43:1, pages 74-78.
Crossref
Crossref
Andrew D. Blann, Giuseppe Boriani & Gregory Y.H. Lip. (2016) Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. Europace 18:10, pages 1507-1513.
Crossref
Crossref
W. Frank Peacock, Zubaid Rafique & Adam J. Singer. (2016) Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. Emergency Medicine International 2016, pages 1-13.
Crossref
Crossref
Ali Zalpour & Thein Hlaing Oo. (2015) Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Advances in Hematology 2015, pages 1-19.
Crossref
Crossref